Effect of IL-18BP on Fractalkine chemokine expression in the kidney tissue of rats with renal fibrosis

WANG Li-Min; LI Chun-Yu; ZHANG Jia-Bin; WANG Yu; CHI Ying-Jiao; YUAN Jing-Wei; ZHANG Ying-Jie

doi:10.7499/j.issn.1008-8830.2013.12.024

PDF(3995 KB)

Chinese Journal of Contemporary Pediatrics ›› 2013, Vol. 15 ›› Issue (12) : 1134-1138. DOI: 10.7499/j.issn.1008-8830.2013.12.024

EXPERIMENTAL RESEARCH

Effect of IL-18BP on Fractalkine chemokine expression in the kidney tissue of rats with renal fibrosis

WANG Li-Min, LI Chun-Yu, ZHANG Jia-Bin, WANG Yu, CHI Ying-Jiao, YUAN Jing-Wei, ZHANG Ying-Jie

Author information +

History +

Abstract

Objective To study the expression of Fractalkine (FKN) in the kidney tissue of rats with renal fibrosis and the effect of IL-18BP on FKN. Methods Male Wister rats were randomly assigned to sham-operation (n=24), unilatral ureteral obstruction (UUO, n=22), and IL-18 binding protein (IL-18BP) treatment groups (n=23). The UUO model was prepared by unilateral ureteral ligation in the later two groups. The IL-18BP treatment group received an intraperitoneal injection of IL-18BP (0.1 mg/kg) every other day after UUO inducement, for 7 times, while normal saline was administered in the other two groups. Seven or eight rats of every group were sacrificed at 3, 7 or 14 days after IL-18BP or normal saline injections. FKN levels at various times were detected by immunohistochemistry and Western blot. Results Compared with the sham-operation group, FKN levels in the kidney tissue of the untreated UUO group increased significantly at all time points (P<0.01). IL-18BP treatment decreased significantly FKN levels in the kidney tissue at all time points compared with the untreated UUO group (P<0.01). Conclusions IL-18BP treatment may down-regulate the increased FKN levels of the rat kidney tissue caused by UUO, possibly thus delays the occurrence and development of renal fibrosis.

Key words

Renal fibrosis / Fractalkine / Interleukin-18 binding protein / Rats

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

WANG Li-Min, LI Chun-Yu, ZHANG Jia-Bin, WANG Yu, CHI Ying-Jiao, YUAN Jing-Wei, ZHANG Ying-Jie. Effect of IL-18BP on Fractalkine chemokine expression in the kidney tissue of rats with renal fibrosis[J]. Chinese Journal of Contemporary Pediatrics. 2013, 15(12): 1134-1138 https://doi.org/10.7499/j.issn.1008-8830.2013.12.024

References

[1] Koziolek MJ, Muller GA, Zapf A, Patschan D, Schmid H, Cohen CD, et al. Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure[J]. Nephrol Dial Transplant, 2010, 25(3): 684-698.
[2] Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis[J]. Am J Physiol Renal Physiol, 2002, 283(5): F861-F875.
[3] Yang XP, Mattagajasingh S, Su S, Chen G, Cai Z, Fox-Talbot K, et al. Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway[J]. Circ Res, 2007, 9(10): 1001-1008.
[4] Saederup N, Chan L, Lira SA, Charo IF. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/-mice: evidence for independent chemokine functions in atherogenesis[J]. Circulation, 2008, 117(13): 1642-1648.
[5] 常贺, 李刚, 张乐, 邹军, 朱铉, 金鑫. IL-18, IL-12 及相关因子在大鼠实验性自身免疫心肌炎心肌中的表达时程和特征[J]. 免疫学杂志, 2010, 26(6): 502-506.
[6] 姜红堃, 罗钢, 姜红. 白细胞介素18在激素耐药型肾病综合征外周血单个核细胞中的表达及意义[J]. 中国当代儿科杂志, 2009, 11(5): 337-340.
[7] 王丽敏, 亚瑟尔. IL-18BP联合泼尼松治疗阿霉素肾病大鼠的实验研究[J]. 黑龙江医药科学, 2012, 35(3): 1-3.
[8] Wang J, Long Q, Zhang W, Chen N. Protective effects of exogenous interleukin 18-binding protein in a rat model of acute renal ischemia-reperfusion injury[J]. Shock, 2012, 37(3): 333-340.
[9] Bani-Hani AH, Leslie JA, Asanuma H, Dinarello CA, Campbell MT, Meldrum DR, et al. IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis[J]. Kidney Int, 2009, 76(5): 500-511.
[10] 王丽敏, 邓李玲, 郑婵娟, 赵塔娜, 邹艳红, 李春玉. 白介素-18结合蛋白对阿霉素肾病大鼠Fractalkine表达的影响[J]. 临床儿科杂志, 2012, 30(7): 666-669.
[11] Wyburn KR, Chadban SJ, Kwan T. Interleukin-18 binding protein therapy is protective in adriamycin nephropathy[J]. Am J Physiol Renal Physiol, 2013, 304(1): F68-F76.